Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy - Trial NCT06382103
Access comprehensive clinical trial information for NCT06382103 through Pure Global AI's free database. This phase not specified trial is sponsored by Shanghai Zhongshan Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Zhongshan Hospital
Timeline & Enrollment
N/A
Apr 20, 2024
May 20, 2026
Primary Outcome
Correlation between ctDNA level and recurrence-free survival (RFS),Correlation between specific plasma protein expression level and recurrence-free survival (RFS)
Summary
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to
 potentially improve prediction of long term prognosis and guide treatment options of patients
 with hepatocellular carcinoma underwent surgical resection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06382103
Non-Device Trial